Pelthos Therapeutics to Restate Q1 Results on Convertible Debt Valuation Error

What happened

Pelthos Therapeutics Inc., a Durham, North Carolina-based biological products company, announced in an SEC filing on August 13, 2026, that its audit committee concluded that previously issued financial statements for the quarter ended March 31, 2026, should no longer be relied upon.

The company will restate those financials because of a misapplication of Accounting Standards Codification (ASC) 820, which governs fair value measurements. The error affected the valuation of the company's convertible debt, a type of bond that can be converted into stock.

The restatement will increase the fair value of the convertible debt by $15.8 million, reduce accumulated other comprehensive income by $1.0 million, and increase accumulated deficit by $14.8 million. It will also increase non-cash expense by $14.8 million in the income statement.

The company said the restatement will have no impact on its liquidity, cash position, revenues, operating expenses, or operating loss. It also disclosed a material weakness in internal control over financial reporting related to the valuation of Level 3 fair value measurements of the convertible debt.

The stock fell 2.63% to $24.08 on the day of the announcement, from a previous close of $24.73.

The company plans to file an amended Form 10-Q for the quarter ended March 31, 2026, to reflect the restatement.

The filing

The announcement was made in a Form 8-K filed with the SEC under Item 4.02(a), which requires companies to disclose when they conclude that previously issued financial statements can no longer be relied upon.

Pelthos said the audit committee, in consultation with management, made the determination on August 12, 2026, and discussed the matter with both its predecessor and current independent accounting firms.

The company identified a material weakness in internal controls as of March 31, 2026, specifically related to controls over the valuation and review of Level 3 fair value measurements of its convertible debt. This means the company's controls did not effectively identify and evaluate the valuation impact of certain terms in a subordination agreement entered into in January 2026.

The material weakness relates to provisions in that agreement, including extended payoff terms and a conversion rate reset feature, which were not properly reflected in the fair value calculation.

What this means

A Form 8-K is a current report that companies must file with the SEC to announce significant events that shareholders should know about. Item 4.02 is specifically used to tell investors that previously issued financial statements are no longer reliable, often because of an accounting error.

ASC 820 is the accounting standard that dictates how companies must measure and disclose the fair value of assets and liabilities. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction. Level 3 fair value measurements are those based on unobservable inputs—essentially, the company's own assumptions, because there is no active market for the instrument.

The convertible debt here appears to be a bond that can be converted into common stock. The error involved not properly accounting for terms in a subordination agreement—meaning the debt ranks below other debts in repayment priority—that affected its value. Specifically, extended payoff terms and a conversion rate reset feature should have made the debt more valuable (or less valuable) than the company originally calculated.

A material weakness in internal control means the company's processes for preparing accurate financial statements had a significant flaw. This is a serious issue because it means there is a reasonable possibility that a material misstatement could occur and not be prevented or detected in a timely manner.

The restatement is a non-cash accounting adjustment: it increases reported liabilities and losses on paper but does not affect the company's actual cash balance or operations. The company will issue an amended 10-Q for the affected quarter, and it will also include a description of the weakness and remediation steps in its next quarterly report.